Home/Astellas Pharma/Kenji Yasukawa
KY

Kenji Yasukawa

President and Chief Executive Officer

Astellas Pharma

Astellas Pharma Pipeline

DrugIndicationPhase
Xtandi (enzalutamide)Prostate CancerApproved
Betmiga (mirabegron)Overactive BladderApproved
Prograf (tacrolimus)ImmunosuppressionApproved
Vesicare (solifenacin)Overactive BladderApproved
ASP2215 (gilteritinib)Acute Myeloid LeukemiaApproved
ASP1929Solid TumorsPhase 2
ASP0367Urothelial CarcinomaPhase 3
ASP3652NASHPhase 2